Reported by JoongAng Ilbo / Apr 29, 2021
HoneyNaps announced that it will launch a digital therapy business for treatment in addition to monitoring, analysis, and diagnosis technology of biosignals between sleep. The platform consists of ▲SOMNUM, an artificial intelligence software for diagnosing sleep disorders, ▲MY SOMNUM, a non-contact sleep analysis and coaching solution, and ▲SOMNUM Medella, a digital treatment for insomnia.
The development of this digital treatment for insomnia will be carried out with Professor Seok-Hoon Jeong and researchers from the Department of Psychiatry, Asan Medical Center, Seoul, who took the lead in the development of 'insomnia clinical treatment guidelines' in Korea.
Digital therapeutics are software medical devices (SaMD) for the purpose of preventing, managing, or treating disorders or diseases beyond disease diagnosis, patient monitoring, and decision support. It can be used in the medical field by replacing or in parallel with
‘SOMNUM Medela’, a digital treatment for insomnia, is based on cognitive behavioral therapy, which is recommended as the primary treatment for insomnia patients, and will provide accurate analysis and customized solutions based on individual sleep data.
The global digital therapeutics market is expected to grow from $3.3 billion (about KRW 3.5 trillion) in 2020 to $8.6 billion (about KRW 8.8 trillion) by 2025, growing at a CAGR of 19.9%.
Ahn Soo-young, the head of technology planning team at HoneyNaps, explained, "We have been continuing research on metaverse-based technology to increase the treatment effect by linking with the sleep data measurement and diagnosis technology possessed by HoneyNaps."